Efficacy and safety of Xuebijing in the treatment of critically ill patients with novel coronavirus infection

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300078398

Enrollment

Unknown

Registered

2023-12-07

Start date

2023-02-21

Completion date

Unknown

Last updated

2023-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critically ill patients with novel coronavirus infection

Interventions

Xuebijing injection group:Use Xuebijing injection (Tianjin Chasesun Pharmaceutical Co., Ltd.) Z20040033 in combination with conventional treatment. Dilute 100 milliliters of Xuebijing injection into 1

Control group:The control group was given an equal amount of physiological saline infusion.

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1) Age =18 years old; 2) Nucleic acid test results positive or throat swab antigen positive; 3) Severe EICU patients, APACHE? score =18 points; 4) Voluntarily participate in this clinical study and receive TCM drug treatment; 5) The subject understands and accepts the procedures and restrictions of the study, and the subject or his legal representative signs the informed consent.

Exclusion criteria

Exclusion criteria: 1) Pregnant or lactating women; 2) Before entering the study, the subjects had received convalescent plasma and other clinical trial drugs for novel coronavirus pneumonia; 3) Subjects are allergic to Chinese medicine ingredients or Xuebijing, or allergic subjects; 4) The subjects have serious underlying diseases that affect their survival, including malignant tumors, blood diseases, poisoning, severe malnutrition, HIV, etc.; 5) Continuous use of immunosuppressants or glucocorticoids within the last 6 months, or organ transplantation; 6) People who are participating in clinical trials of other drugs; 7) Those who have other factors that the researcher considers inappropriate to participate in this study.

Design outcomes

Primary

Measure	Time frame
The change of virus load in CT value;	—

Secondary

Measure	Time frame
The change of inflammatory factor in serum and immune cells count;Short term prognosis of the disease;	—

Countries

China

Contacts

Public ContactLuZhongQiu

The First Affiliated Hospital of Wenzhou Medical University

lzq640815@163.com+86 139 5775 9958

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026